Real-Life Testing of the Prescription Opioid Misuse Index in French Primary Care.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
11 11 2022
Historique:
received: 16 09 2022
revised: 08 10 2022
accepted: 26 10 2022
entrez: 26 11 2022
pubmed: 27 11 2022
medline: 30 11 2022
Statut: epublish

Résumé

Analgesic opioid (AO) misuse by patients ranges from 0% to 50%. General practitioners are the first prescribers of AO. Our objective was to validate the Prescription Opioid Misuse Index (POMI) in primary care. We conducted a psychometric study in patients with chronic pain who had been taking AOs for at least 3 months and were followed in general practice. Patients responded to the POMI at inclusion and after 2 weeks. The reference used was the DSM-V. Sixty-nine GPs included 160 patients (87 women, 54.4%), mean age 56.4 ± 15.2 years. The total POMI score was 1.50 ± 1.27, and 73/160 (45.6.0%) had a score ≥ 2 (misuse threshold). Internal validity was measured with the Kuder-Richardson coefficient, which was 0.44. Correlations between each item and the total score ranged from 0.06 to 0.35. Test-retest reliability was determined from 145 patients: Lin's concordance coefficient was 0.57 [0.46, 0.68]. Correlation with the DSM-V (Spearman's coefficient) was 0.52. The POMI does not have sufficient psychometric properties to be recommended as a tool to identify the misuse of AOs in primary care. This study clearly showed that there is a need to create a monitoring tool specific to primary care.

Identifiants

pubmed: 36429565
pii: ijerph192214845
doi: 10.3390/ijerph192214845
pmc: PMC9690529
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Pain Res. 2016 Jun 28;9:457-67
pubmed: 27418853
Eur J Pain. 2010 Nov;14(10):1014-20
pubmed: 20494598
J Clin Epidemiol. 1993 Dec;46(12):1417-32
pubmed: 8263569
Addict Behav. 2017 Oct;73:133-136
pubmed: 28511097
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
Rev Prat. 2010 Dec 20;60(10 Suppl):24-8
pubmed: 22530272
Can J Anaesth. 2022 Aug;69(8):1042-1052
pubmed: 35229249
Rev Med Suisse. 2013 Oct 16;9(402):1917-20
pubmed: 24298716
J Subst Abuse Treat. 2008 Dec;35(4):380-6
pubmed: 18657935
Eur J Pain. 2007 Jul;11(5):490-518
pubmed: 17070082
JAMA. 1995 Aug 23-30;274(8):645-51
pubmed: 7637146
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
Eur J Pain. 2006 May;10(4):287-333
pubmed: 16095934
JAMA. 1999 Sep 15;282(11):1061-6
pubmed: 10493205
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752

Auteurs

Catherine Laporte (C)

Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Frédéric Fortin (F)

Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Julie Dupouy (J)

Unite Mixte de Recherche (UMR) 1295 Inserm, Université Toulouse III, F-31000 Toulouse, France.
Maison de Santé Pluriprofessionelle Universitaire de Pins Justaret, F-31860 Pins Justaret, France.

Aurélie Quirin (A)

Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Bruno Pereira (B)

Unité de Biostatistiques, Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France.

Chouki Chenaf (C)

CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Jessica Delorme (J)

CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Christine Maynié-François (C)

UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive (LBBE), Équipe Evaluation et Modélisation des Effets Thérapeutiques (EMET), Université Claude Bernard Lyon 1, F-69100 Lyon, France.

Cédric Rat (C)

Département de Médecine Générale, Université de Nantes-INSERM U1302/CNRS EMR6001-Équipe 2, F-44035 Nantes, France.

Jordan Birebent (J)

Unite Mixte de Recherche (UMR) 1295 Inserm, Université Toulouse III, F-31000 Toulouse, France.
Maison de Santé Pluriprofessionelle Universitaire de Pins Justaret, F-31860 Pins Justaret, France.

Jacques Rambaud (J)

Département de Médecine Générale, Université Montpellier, F-34090 Montpellier, France.

Christian Duale (C)

Unité de Biostatistiques, Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France.

Nicolas Kerckhove (N)

CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Noémie Delage (N)

CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Nicolas Authier (N)

CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH